Psychedelic Stocks

Four Psychedelics ETF Investors Are Interested In

Renewed interest in psychedelics in both public and scientific spaces has increased investor interest in psychedelic stocks. The psychedelic market is projected to achieve a valuation of $10.7 billion by 2027, and investors are looking to cash in on the industry before it is saturated. However, the industry is still in its infancy and presents a high degree of risk.

As such, psychedelic ETFs or exchange-traded funds that allow investors to buy a bundle of several stocks rather than one have been the focal point of investor interest as they allow diversified risk. Below are a couple of ETFs investors have shown interest in:

Defiance Next Gen Altered Experience ETF (NYSE: PSY) is managed passively based on weighted market cap. It tracks the BITA Medical Psychedelics, Cannabis and Ketamine Index. PSY currently has 21 stocks and manages nearly $8 million; a share was priced at $4.93 as of June 16. Defiance ETF first deployed the psychedelic-focused EFT in May with a focus on licensed companies that deal with psychedelics, cannabis and ketamine.

To be included in this particular index, these companies have to generate at least 50% of their revenue from the production and sale of medical cannabis, psychedelics or ketamine.

Horizon’s Psychedelic Stock Index ETF (NEO: PSYK) trades on the Canadian Stock Index. It tracks North America’s psychedelics market based on a weighted market cap but isn’t as actively managed as PSIL. It manages around $21 million (CAD), has invested in 20 psychedelic stocks and was trading at $2.65 on the Canadian Stock Index as of June 16.

The Advisor Shares Psychedelics ETF (NYSE: PSIL) is actively managed. This EFT boasts stock analysts and dedicated researchers who examine market factors and dive into company financial records to decide which ones to add to PSIL. The ETF has invested capital into 28 psychedelic stocks and currently manages $5.9 million. It was trading at $2.71 as of June 16.

The Elemental Advisors ETF (NYSE: PSYK) is another psychedelics EFT that is managed passively on weighted market cap with one caveat: it uses a proprietary algorithm that processes natural language to choose psychedelic companies. Elemental advisors launched the EFT in February to track the Enhanced Consciousness Index. This index mainly consists of licensed companies that are primarily associated with the research, development and production of psychedelics for medical use.

It is a relatively small EFT compared to the previous three, with just $706,561 in its management. It was trading at $17.14 on the New York Stock Exchange as of June 16.

It might also be wise for you to do your own research about companies such as Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) in the portfolios of the different ETFs you are considering so that you can be sure that only the best stocks have been given prominence.

NOTE TO INVESTORS: The latest news and updates relating to Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) are available in the company’s newsroom at https://ibn.fm/DELCF

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)

For more information please visit https://www.psychedelicnewswire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com

PsychedelicNewsWire is part of the InvestorBrandNetwork.

Chris@PNW

Share
Published by
Chris@PNW

Recent Posts

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Files Abbreviated New Drug Application for Preservative-Free IV Ketamine NRX-100 Amid Ongoing Shortage

The company targets all current ketamine indications, including anesthesia and pain management. The U.S. is…

4 days ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Signs Agreement to Acquire Kadima to Launch $100M Psychiatry Clinic Network

The Kadima Neuropsychiatry Institute acquisition is part of NRx subsidiary HOPE Therapeutics’ model for a…

1 week ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Announces $10.3 Million Financing to Expand HOPE Clinic Network, Advances FDA Drug Approval

Subsidiary HOPE Therapeutics signed a $7.8 million debt financing term sheet with Universal Capital. Combined…

3 weeks ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Subsidiary, HOPE Therapeutics, to Expand Interventional Psychiatry Treatment with Kadima Institute Acquisition

Kadima Neuropsychiatry Institute is expected to become the clinical model for HOPE Therapeutics’ nationwide network…

3 weeks ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Is ‘One to Watch’

NRx Pharmaceuticals is advancing a pipeline of innovative therapies targeting multibillion-dollar unmet needs in central…

4 weeks ago

Republican Lawmakers Embrace Psychedelic Therapies in Shift Toward Veteran Mental Health Reform

Rep. Morgan Luttrell (R-Texas), a retired Navy SEAL, is part of a rising wave of…

4 weeks ago